Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.46 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838008 | 0.84 | ADK (0.67) | ADKTP53SMN1; SMN2HSPA5HSPA8 | |
| SCHEMBL20973122 | 0.81 | ADK (0.47) | ADKHSPA5HSPA8SLC29A1RXFP1 | |
| SCHEMBL21369239 | 0.80 | ADK (0.47) | ADKHSPA5HSPA8SLC29A1RXFP1 | |
| SCHEMBL21368800 | 0.77 | ADK (0.52) | ADKHSPA5HSPA8SLC29A1RXFP1 | |
| SCHEMBL19837981 | 0.77 | ADK (0.67) | ADKHSPA5HSPA8SLC29A1RXFP1 | |
| SCHEMBL21351720 | 0.77 | ADK (0.67) | ADKHSPA5HSPA8SLC29A1RXFP1 | |
| SCHEMBL17816360 | 0.74 | SLC29A1 (0.70) | SLC29A1 | |
| SCHEMBL17816343 | 0.73 | ADK (0.56) | ADKTP53SLC29A1 | |
| SCHEMBL17800872 | 0.73 | ADK (0.66) | ADKTP53 | |
| SCHEMBL17800863 | 0.72 | ADK (0.74) | ADKTP53SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730905-B2 | Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2020-08-04 | — | — | US | disclosed |
| EP-3494122-B1 | SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-09-18 | — | — | EP | disclosed |
| EP-3494122-A1 | SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2019-06-12 | — | — | EP | disclosed |
| US-20190144486-A1 | SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-05-16 | — | — | US | disclosed |
| WO-2018024265-A1 | SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730905-B2 | Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use | DPYD, MTAP, TYMP | ADK 664/4885TP53 617/4885SMN1; SMN2 686/4885 |
| US-20190144486-A1 | SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | DPYD, MTAP, TYMP | ADK 664/4885TP53 617/4885SMN1; SMN2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.